STOCK TITAN

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of - TAK STOCK NEWS

Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.

Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.

With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.

Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.

Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.

Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.

Rhea-AI Summary

VONVENDI ([von Willebrand Factor (Recombinant)]) has received FDA approval for routine prophylaxis to reduce bleeding episodes in adults with severe Type 3 von Willebrand disease (VWD) on on-demand therapy. This marks it as the first treatment specifically for this purpose. VWD affects up to 3 million people in the U.S., impacting blood clotting due to a deficiency or dysfunction of von Willebrand factor. Clinical studies showed a 54.7% reduction in annualized bleeding rates. The approval reflects Takeda's commitment to improving care for individuals with VWD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary

Takeda Pharmaceutical Company announced its growth strategy and revenue potential at the J.P. Morgan Healthcare Conference. The company is optimistic about generating incremental revenue of JPY 500 billion (approximately $4.5 billion) by FY2025, supported by 14 global brands projected to grow by 14-16%. Takeda's pipeline includes 40 clinical-stage therapies, targeting oncology and rare diseases, aiming for significant regulatory approvals. The company is also committed to maintaining strong cash flow and reducing debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
Rhea-AI Summary

Takeda Pharmaceutical Company Limited has announced its acquisition of Adaptate Biotherapeutics, enhancing its immuno-oncology portfolio. This acquisition follows a successful partnership and marks Takeda's third oncology 'build-to-buy' initiative in under a year. The deal focuses on Adaptate's antibody-based γδ T-cell engager platform aimed at cancer therapies, complementing previous acquisitions. This strategic move positions Takeda at the forefront of γδ T cell research, expected to finalize in Q1 of Takeda's fiscal year 2022, pending regulatory reviews.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (NYSE: TAK) has received a Complete Response Letter (CRL) from the U.S. FDA regarding its New Drug Application for TAK-721 (budesonide oral suspension) aimed at treating eosinophilic esophagitis (EoE). The FDA indicated that the application could not be approved in its current state and recommended further clinical studies. Takeda expressed disappointment, noting that patients will continue to lack an FDA-approved treatment option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of vedolizumab for the treatment of adults with moderately to severely active chronic pouchitis. If approved, vedolizumab would be the first authorized treatment for this condition in Europe, which affects patients post-surgery for ulcerative colitis. The positive opinion was based on findings from the EARNEST trial, showing significant clinical remission rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
Rhea-AI Summary

Takeda Pharmaceutical Company presented nine abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting held from December 11-14, 2021. The presentations highlight their commitment to innovative treatments in hematology, including data on ADYNOVATE for severe hemophilia A and an analysis of joint health biomarkers. Notably, the design of a phase 3b study of TAK-755, a first-of-its-kind replacement therapy, was shared. This emphasizes Takeda's ongoing advancements in therapies for rare blood disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
-
Rhea-AI Summary

Takeda Pharmaceutical Company released results from the pivotal Phase 3 SOLSTICE trial, showing that LIVTENCITY (maribavir) significantly outperformed conventional therapies in treating post-transplant CMV infections. The primary endpoint was met with 55.7% of patients on LIVTENCITY achieving CMV DNA levels below 137 IU/mL compared to 23.9% for conventional therapies. Additionally, the key secondary endpoint of symptom control was also significantly better for LIVTENCITY. Adverse events were similar between groups, but fewer LIVTENCITY patients discontinued due to adverse events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
-
Rhea-AI Summary

Takeda Pharmaceutical Company (TSE:4502/NYSE:TAK) announced it will present 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021 in Atlanta, Georgia. The presentations focus on advancing treatments in oncology and hematology, featuring pipeline candidates like Modakafusp Alfa (TAK-573) and Subasumstat (TAK-981). A key highlight includes updates on TAK-755, a novel therapy for Sickle Cell Disease and Congenital Thrombotic Thrombocytopenic Purpura.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
none
Rhea-AI Summary

Takeda Pharmaceutical Company announced the U.S. launch of LIVTENCITY™ (maribavir), the first treatment for post-transplant cytomegalovirus (CMV) infection/disease resistant to conventional antivirals. Available since December 2, 2021, after receiving FDA approval on November 23, LIVTENCITY is designed for patients aged 12 and over weighing at least 35 kg. With an estimated incidence rate of 16%-70% in transplant recipients, CMV poses serious health risks, emphasizing the need for effective treatments. LIVTENCITY offers a new option for clinicians in managing this complex infection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none

FAQ

What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is $13.17 as of December 24, 2024.

What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is approximately 41.8B.

What are Takeda Pharmaceutical's core therapeutic areas?

Takeda focuses on oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

Where is Takeda Pharmaceutical headquartered?

Takeda is headquartered in Tokyo, Japan.

What recent collaborations has Takeda Pharmaceutical entered into?

Takeda recently entered a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation to incubate early drug discovery programs.

How diversified is Takeda's revenue geographically?

Takeda's revenue is geographically diversified: 50% from the US, 20% from Japan, and 20% from Europe and Canada.

What was Takeda's revenue in fiscal 2023?

Takeda's revenue in fiscal 2023 was JPY 4.3 trillion.

Who can benefit from Takeda's new drug NBI-1065845?

NBI-1065845 is targeted at patients with major depressive disorder who have not benefited from at least one existing antidepressant treatment.

What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?

The joint venture focuses on incubating early drug discovery programs to advance academic discoveries into practical medical treatments.

How long has Takeda been in the pharmaceutical industry?

Takeda has been a leader in the pharmaceutical industry for over two centuries.

In how many countries does Takeda operate?

Takeda operates in approximately 80 countries.

How does Takeda contribute to the field of major depressive disorder treatment?

Takeda collaborates with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment showing positive Phase 2 results for MDD.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of

NYSE:TAK

TAK Rankings

TAK Stock Data

41.75B
3.17B
0.01%
2.45%
0.18%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tokyo